Analysis of effectiveness of NCL1, a highly selective lysine-specific demethylase 1 inhibitor, for prostate cancer
| Project/Area Number |
26861284
|
|---|
| Research Category |
Grant-in-Aid for Young Scientists (B)
|
| Allocation Type | Multi-year Fund |
|---|
| Research Field |
Urology
|
|---|
| Research Institution | Nagoya City University |
|---|
Principal Investigator |
ETANI TOSHIKI 名古屋市立大学, 医学(系)研究科(研究院), 研究員 (30600754)
|
|---|
| Project Period (FY) |
2014-04-01 – 2016-03-31
|
| Project Status |
Completed (Fiscal Year 2015)
|
| Budget Amount *help |
¥3,250,000 (Direct Cost: ¥2,500,000、Indirect Cost: ¥750,000)
Fiscal Year 2015: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Fiscal Year 2014: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
|
|---|
| Keywords | エピジェネティクス / ヒストン修飾 / LSD1 / 前立腺癌 / オートファジー / LSD1阻害 / 細胞周期停止 / アポトーシス / 動物モデル |
|---|
| Outline of Final Research Achievements |
We investigated therapeutic potential of a novel histone lysine demethylase 1 (LSD1) inhibitor, NCL1, in prostate cancer. Prostate cancer cells, LNCaP, PC3 and PCai1 were treated with NCL1, and LSD1 expression and cell viability were assessed. Prostate cancer cells showed strong LSD1 expression, and cell viability was decreased by NCL1. NCL1 also induced G1 cell cycle arrest and apoptosis. In addition, autophagosomes and autolysosomes were induced by NCL1 treatment in LNCaP. Furthermore, LC3-II expression was significantly increased by NCL1 and chloroquine. In mice injected subcutaneously with PCai1 and intraperitoneally with NCL1, tumor volume was reduced with no adverse effects in NCL1-treated mice. Finally, LSD1 expression in human cancer specimens was significantly higher than that in normal prostate glands. NCL1 effectively suppressed prostate cancer growth without adverse events. We suggest that NCL1 is a potential therapeutic agent for hormone-resistant prostate cancer.
|
Report
(3 results)
Research Products
(12 results)
-
[Journal Article] NCL1, a highly selective lysine-specific demethylase 1 inhibitor, suppresses prostate cancer without adverse effect.2015
Author(s)
Etani Toshiki, Suzuki Takayoshi, Naiki Taku, Naiki-Ito Aya, Ando Ryosuke, Iida Keitaro, Kawai Noriyasu, Tozawa Keiichi, Miyata Naoki, Kohri Kenjiro, Takahashi Satoru
-
Journal Title
Oncotarget
Volume: 6
Issue: 5
Pages: 2865-2878
DOI
Related Report
Peer Reviewed / Open Access / Acknowledgement Compliant
-
-
-
[Presentation] NCL1, a selective lysine-specific demethylase1 inhibitor suppresses castration resistant prostate cancer growth2015
Author(s)
Etani Toshiki, Naiki Taku, Iida Keitaro, Ando Ryosuke, Kobayashi Daichi, Kawai Noriyasu, Tozawa Keiichi, Suzuki Takayoshi, Takahasi Satoru, Kohri Kenjiro, Yasui Takahiro
Organizer
第74回日本癌学会学術総会
Place of Presentation
名古屋国際会議場（愛知県名古屋市）
Year and Date
2015-10-08
Related Report
-
-
-
-
-
-
-
-
